HUP0203375A2 - Szubsztituált oxoazaheterociklusos vegyületek - Google Patents
Szubsztituált oxoazaheterociklusos vegyületekInfo
- Publication number
- HUP0203375A2 HUP0203375A2 HU0203375A HUP0203375A HUP0203375A2 HU P0203375 A2 HUP0203375 A2 HU P0203375A2 HU 0203375 A HU0203375 A HU 0203375A HU P0203375 A HUP0203375 A HU P0203375A HU P0203375 A2 HUP0203375 A2 HU P0203375A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- fused
- cycloalkenyl
- attached carbon
- mean
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 8
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004434 sulfur atom Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000003431 oxalo group Chemical group 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Dental Preparations (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
A találmány szerinti vegyületek (I) általános képletében G1 és G2jelentése L1-Cy1, vagy L2-Cy2 csoport, azzal a megszorítással, hogy haR1 és R1a és R4 és R4a jelentése együtt oxigénatom vagy kénatom, akkorG1 jelentése L2Cy2 csoport és G2 jelentése L1-Cy1 csoport, vagy ha R2és R2a vagy R3 és R3a jelentése együtt oxigénatom vagy kénatom, akkorG1 jelentése L1-Cy1 és G2 jelentése L2CY2, Cy1 és Cy2 jelentéseegymástól függetlenül egyenként adott esetben szubsztituáltarilcsoport, heteroarilcsoport, cikloalkilcsoport,cikloalkenilcsoport, heterociklusos csoport, heterociklenilcsoport,fúzionált arilcikloalkilcsoport, fúzionált arilcikloalkenilcsoport,fúzionált arilheterociklusoscsoport, fúzionáltarilheterociklenilcsoport, fúzionált heteroarilcikloalkilcsoport,heteroarilcikloalkenilcsoport, fúzionáltheteroarilheterociklusoscsoport vagy fúzionáltheteroarilheterociklenilcsoport, L1 jelentése közvetlen kötés, -O-, -NR5-, -S(O)p-, -S(O)pNR5-, -C(X)Y-, -L3-Q-L4-Q'-L5-, -G(O)Y-C(X)Y-, -C(X)YC(O)-, -C(O) NR5-S(O)p- vagy -C(O)C(O)NR5S(O)p- képletű csoport,L2 jelentése közvetlen kötés vagy (a) általános képletű csoport, Ajelentése CH vagy N, R1, R1a, R2, R2a, R3, R3a, R4 és R4a jelentéseegymástól függetlenül hidrogénatom, karboxilcsoport,alkoxikarbonilcsoport, Y1Y2NC(O)- képletű csoport vagy egyenként,adott esetben szubsztituált alkilcsoport, arilcsoport, aralkilcsoport,heteroarilcsoport vagy heteroaralkilcsoport, vagy R1 és R1a, R2 ésR2a, R3 és R3a vagy R4 és R4a jelentése együtt oxigénatom vagykénatom, vagy R1 és R2 jelentése a kapcsolódó szénatomokkal együttcikloalkenilcsoport, heterociklusos csoport vagyheterociklenilcsoport, vagy R3 és R4 jelentése a kapcsolódószénatomokkal együtt cikloalkenilcsoport, heterociklusos csoport vagyheterociklenilcsoport, vagy R1a és R2a hiányzik és R1 és R2 jelentésea kapcsolódó szénatomokkal együtt arilcsoport vagy heteroarilcsoport,vagy R3a és R4a hiányzik, és R3 és R4 jelentése a kapcsolódószénatomokkal együtt arilcsoport vagy heteroarilcsoport, vagy egy vagytöbb pár R1 és R1a a kapcsolódó szénatommal együtt cikloalkilcsoportotvagy cikloalkenilcsoportot képez, vagy R2 és R2a a kapcsolódószénatommal együtt cikloalkilcsoportot vagy cikloalkenilcsoportotképez, vagy R3 és R3a a kapcsolódó szénatommal együttcikloalkilcsoportot vagy cikloalkenilcsoportot képez, vagy R4 és R4a akapcsolódó szénatommal együtt cikloalkilcsoportot vagycikloalkenilcsoportot képez, m és n értéke egymástól függetlenül 0, 1vagy 2. A találmány kiterjed a fenti vegyületeket tartalmazógyógyszerkészítményekre, és a vegyületek előállítására alkalmazottintermedierekre. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36319699A | 1999-07-28 | 1999-07-28 | |
PCT/IB2000/001156 WO2001007436A2 (en) | 1999-07-28 | 2000-07-26 | Substituted oxoazaheterocyclyl compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0203375A2 true HUP0203375A2 (hu) | 2002-12-28 |
HUP0203375A3 HUP0203375A3 (en) | 2005-03-29 |
Family
ID=23429232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0203375A HUP0203375A3 (en) | 1999-07-28 | 2000-07-26 | Substituted oxoazaheterocyclyl compounds |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1208097B1 (hu) |
JP (1) | JP4829449B2 (hu) |
KR (1) | KR20020087041A (hu) |
CN (1) | CN1420882A (hu) |
AT (1) | ATE423113T1 (hu) |
AU (1) | AU773227B2 (hu) |
BG (1) | BG106340A (hu) |
BR (1) | BR0013179A (hu) |
CA (1) | CA2382755A1 (hu) |
CR (1) | CR6563A (hu) |
CZ (1) | CZ2002323A3 (hu) |
DE (1) | DE60041584D1 (hu) |
EE (1) | EE200200045A (hu) |
HK (1) | HK1054227A1 (hu) |
HR (1) | HRP20020076A2 (hu) |
HU (1) | HUP0203375A3 (hu) |
IL (2) | IL147495A0 (hu) |
MX (1) | MXPA02000888A (hu) |
NO (1) | NO20020214L (hu) |
PL (1) | PL354998A1 (hu) |
RU (1) | RU2002105011A (hu) |
SK (1) | SK1182002A3 (hu) |
TR (1) | TR200200225T2 (hu) |
WO (1) | WO2001007436A2 (hu) |
ZA (1) | ZA200200543B (hu) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA005893B1 (ru) | 2000-03-21 | 2005-06-30 | Смитклайн Бичам Корпорейшн | Ингибиторы протеаз |
US20040072860A1 (en) * | 2000-09-29 | 2004-04-15 | Bing-Yan Zhu | Piperazin-2-one amides as inhibitors of factor xa |
ES2387981T3 (es) * | 2001-02-02 | 2012-10-05 | Bristol-Myers Squibb Company | Composición y actividad antiviral de derivados de piperazina azaindoloxoacética sustituidos |
GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
GB0114004D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
GB0114005D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
IL159256A0 (en) | 2001-07-02 | 2004-06-01 | Astrazeneca Ab | Piperidine derivatives useful as modulators of chemokine receptor activity |
GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
AU2007229363B2 (en) * | 2001-08-24 | 2009-06-04 | University Of South Florida | Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and the Methods of Treatment |
ATE530184T1 (de) | 2001-08-24 | 2011-11-15 | Univ Yale | Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe |
GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
AU2003218028A1 (en) | 2002-03-08 | 2003-09-22 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
WO2003087089A1 (fr) | 2002-04-16 | 2003-10-23 | Teijin Limited | Derives de piperidine possedant un antagonisme de ccr3 |
CN100360521C (zh) | 2002-04-25 | 2008-01-09 | 帝人株式会社 | 具有ccr3拮抗作用的4,4-二取代的哌啶衍生物 |
TW200409637A (en) | 2002-06-26 | 2004-06-16 | Glaxo Group Ltd | Compounds |
WO2004032930A1 (ja) * | 2002-10-11 | 2004-04-22 | Kowa Co., Ltd. | 癌の処置方法 |
US7358268B2 (en) | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
US8729107B2 (en) | 2002-12-06 | 2014-05-20 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
DE60329415D1 (de) | 2002-12-06 | 2009-11-05 | Purdue Research Foundation | Pyridine zur behandlung von verletztemsäugetiernervengewebe |
US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
WO2004078715A1 (ja) | 2003-03-07 | 2004-09-16 | Astellas Pharma Inc. | 2,6-ジ置換スチリルを有する含窒素へテロ環誘導体 |
SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
US7317027B2 (en) | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
EP1479675A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
DK1558582T3 (da) | 2003-07-22 | 2006-05-08 | Arena Pharm Inc | Diaryl og arylheteroarylureaderivater som modulatorer af aktiviteten af 5-HT2A-serotoninreceptoren anvendelige til profylakse eller behandling af forstyrrelser relateret dertil |
SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
US7393865B2 (en) | 2004-06-17 | 2008-07-01 | Neurocrine Biosciences, Inc. | Sleep inducing compounds and methods relating thereto |
GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
PL1849773T3 (pl) | 2005-02-17 | 2014-03-31 | Astellas Pharma Inc | Pochodne piperazyny do leczenia nietrzymania moczu i bólu |
WO2007008144A1 (en) * | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
WO2007008146A1 (en) * | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
CA2615650A1 (en) | 2005-07-21 | 2007-01-25 | Astrazeneca Ab | Novel piperidine derivatives |
US8143285B2 (en) * | 2005-09-06 | 2012-03-27 | Shionogi & Co., Ltd. | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity |
WO2007038215A1 (en) | 2005-09-22 | 2007-04-05 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
BRPI0616574A2 (pt) | 2005-09-27 | 2009-11-24 | Shionogi & Co | derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2 |
ES2443242T3 (es) | 2005-12-23 | 2014-02-18 | Zealand Pharma A/S | Compuestos modificados miméticos de lisina |
EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
WO2007118130A2 (en) | 2006-04-06 | 2007-10-18 | Glaxo Group Limited | Antibacterial agents |
US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
WO2007140263A2 (en) * | 2006-05-26 | 2007-12-06 | University Of Louisville Research Foundation, Inc. | Macrophage migration inhibitory factor antagonists and methods of using same |
EP1882688A1 (en) * | 2006-07-25 | 2008-01-30 | EPFL Ecole Polytechnique Fédérale de Lausanne | Labelling of fusion proteins with synthetic probes |
TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物 |
EP2074087A2 (en) | 2006-12-21 | 2009-07-01 | Wyeth | Synthesis of pyrrolidine compounds |
SI2069324T1 (sl) * | 2007-03-20 | 2013-10-30 | Curis, Inc. | Kondenzirani aminopiridini kot HSP90-inhibitorji |
WO2009023253A2 (en) | 2007-08-15 | 2009-02-19 | Arena Pharmaceuticals Inc. | IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
TW200944526A (en) | 2008-04-22 | 2009-11-01 | Vitae Pharmaceuticals Inc | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
CN102264354B (zh) | 2008-10-28 | 2015-03-25 | 艾尼纳制药公司 | 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物 |
US9162987B2 (en) | 2009-09-24 | 2015-10-20 | University Of Louisville Research Foundation, Inc. | Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions |
US9155790B2 (en) | 2010-05-20 | 2015-10-13 | University of Lousiville Research Foundation, Inc. | Methods and compositions for modulating ocular damage |
KR101251282B1 (ko) | 2010-10-18 | 2013-04-10 | 서울대학교산학협력단 | 프로스타글란딘 합성을 억제하는 설폰아미드 유도체 및 이를 포함하는 약학적 조성물 |
CN102532159B (zh) * | 2010-11-12 | 2015-02-11 | 姚雪彪 | 动点马达蛋白CENP-E小分子抑制剂Syntelin |
US8980924B2 (en) | 2010-11-24 | 2015-03-17 | The Trustees Of Columbia University In The City Of New York | Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease |
PL395470A1 (pl) | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego |
US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
US9637450B2 (en) | 2013-03-14 | 2017-05-02 | The Trustees Of Columbia University In The City Of New York | Octahydrocyclopentapyrroles, their preparation and use |
EP2968304B1 (en) | 2013-03-14 | 2018-10-10 | The Trustees of Columbia University in the City of New York | 4-phenylpiperidines, their preparation and use |
BR112016025356B1 (pt) | 2014-04-30 | 2023-04-18 | The Trustees Of Columbia University In The City Of New York | Compostos de 4-fenilpiperidinas substituídas, composições e seus usos |
CA2954212C (en) | 2014-07-31 | 2023-09-19 | Basf Se | Process for preparing pyrazoles |
CN104557927B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构的凝血因子Xa抑制剂及其用途 |
CN104650081B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 凝血因子Xa抑制剂、制备方法及其用途 |
CN104672235B (zh) * | 2015-02-14 | 2016-02-17 | 佛山市赛维斯医药科技有限公司 | 一类含双酰胺基和烷氧苯基结构的FXa抑制剂及其用途 |
CN104557929B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含二环酰胺结构的凝血因子Xa抑制剂及其用途 |
CN104592227B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺和卤代苯结构的FXa抑制剂、制备方法及其用途 |
CN104650082B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类凝血因子Xa抑制剂、制备方法及其用途 |
CN104557928B (zh) * | 2015-02-14 | 2016-08-24 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构凝血因子Xa抑制剂、其制备方法及其用途 |
CN104672236B (zh) * | 2015-02-14 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 一类含双酰胺基和卤代苯结构的FXa抑制剂及其用途 |
CN104610258B (zh) * | 2015-02-14 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺和甲氧苯结构的FXa抑制剂、制备方法及其用途 |
CN104610257B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺结构的FXa抑制剂、制备方法及其用途 |
CN104610259B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途 |
CN104610260B (zh) * | 2015-02-14 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途 |
CN104557930B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构凝血因子Xa抑制剂及其用途 |
CA3187499A1 (en) | 2015-05-11 | 2016-11-17 | Eric George KLAUBER | Process for preparing 4-amino-pyridazines |
MX2017016413A (es) | 2015-06-12 | 2018-08-01 | Axovant Sciences Gmbh | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem. |
PE20180500A1 (es) | 2015-06-26 | 2018-03-09 | Takeda Pharmaceuticals Co | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1 |
RU2018103338A (ru) | 2015-07-15 | 2019-08-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием |
JP6787913B2 (ja) * | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
WO2018082964A1 (en) | 2016-11-04 | 2018-05-11 | Basf Se | Process for the production of pyridazinyl-amides in a one-pot synthesis |
JP7145875B2 (ja) | 2017-04-18 | 2022-10-03 | 武田薬品工業株式会社 | アセチルコリン受容体のモジュレーターとして有用な複素環化合物 |
US11324799B2 (en) | 2017-05-05 | 2022-05-10 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
CN110054619A (zh) * | 2018-01-18 | 2019-07-26 | 西北农林科技大学 | 新型二酮哌嗪类组蛋白去乙酰化酶抑制剂 |
BR112020020663A2 (pt) | 2018-04-10 | 2021-01-12 | Bayer Aktiengesellschaft | Derivados de oxadiazolina |
CN109991355B (zh) * | 2019-04-12 | 2021-05-11 | 中国烟草总公司郑州烟草研究院 | 一种鉴定动物体内nab代谢产物的方法和评价nab在动物体内暴露风险的方法 |
WO2022228387A1 (en) * | 2021-04-26 | 2022-11-03 | Fochon Biosciences, Ltd. | Compounds as parp inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994018981A1 (en) * | 1993-02-22 | 1994-09-01 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
UA56197C2 (uk) * | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Гетероциклічні похідні |
US6211183B1 (en) * | 1997-04-14 | 2001-04-03 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
EP1048652A4 (en) * | 1997-12-26 | 2001-05-09 | Mochida Pharm Co Ltd | AROMATIC COMPOUNDS WITH A CYCLIC AMINO GROUP OR THEIR SALTS |
AU745425B2 (en) * | 1998-01-27 | 2002-03-21 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl factor Xa inhibitors |
WO1999040075A1 (fr) * | 1998-02-05 | 1999-08-12 | Takeda Chemical Industries, Ltd. | Derives de sulfamide, leur procede de production et leur utilisation |
JP2000204081A (ja) * | 1998-02-05 | 2000-07-25 | Takeda Chem Ind Ltd | スルホンアミド誘導体、その製造法及び用途 |
JP2003529531A (ja) * | 1998-11-25 | 2003-10-07 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 置換オキソアザへテロシクリルXa因子阻害剤 |
-
2000
- 2000-07-26 KR KR1020027001192A patent/KR20020087041A/ko not_active Application Discontinuation
- 2000-07-26 EP EP00951781A patent/EP1208097B1/en not_active Expired - Lifetime
- 2000-07-26 PL PL00354998A patent/PL354998A1/xx not_active Application Discontinuation
- 2000-07-26 IL IL14749500A patent/IL147495A0/xx active IP Right Grant
- 2000-07-26 MX MXPA02000888A patent/MXPA02000888A/es active IP Right Grant
- 2000-07-26 DE DE60041584T patent/DE60041584D1/de not_active Expired - Lifetime
- 2000-07-26 CA CA002382755A patent/CA2382755A1/en not_active Abandoned
- 2000-07-26 AT AT00951781T patent/ATE423113T1/de not_active IP Right Cessation
- 2000-07-26 CN CN00810877A patent/CN1420882A/zh active Pending
- 2000-07-26 BR BR0013179-2A patent/BR0013179A/pt not_active IP Right Cessation
- 2000-07-26 EE EEP200200045A patent/EE200200045A/xx unknown
- 2000-07-26 CZ CZ2002323A patent/CZ2002323A3/cs unknown
- 2000-07-26 SK SK118-2002A patent/SK1182002A3/sk unknown
- 2000-07-26 AU AU64628/00A patent/AU773227B2/en not_active Ceased
- 2000-07-26 JP JP2001512520A patent/JP4829449B2/ja not_active Expired - Fee Related
- 2000-07-26 WO PCT/IB2000/001156 patent/WO2001007436A2/en active Search and Examination
- 2000-07-26 RU RU2002105011/04A patent/RU2002105011A/ru unknown
- 2000-07-26 HU HU0203375A patent/HUP0203375A3/hu unknown
- 2000-07-26 TR TR2002/00225T patent/TR200200225T2/xx unknown
-
2002
- 2002-01-06 IL IL147495A patent/IL147495A/en not_active IP Right Cessation
- 2002-01-15 NO NO20020214A patent/NO20020214L/no not_active Application Discontinuation
- 2002-01-22 ZA ZA200200543A patent/ZA200200543B/en unknown
- 2002-01-22 BG BG106340A patent/BG106340A/xx unknown
- 2002-01-25 CR CR6563A patent/CR6563A/es unknown
- 2002-01-25 HR HR20020076A patent/HRP20020076A2/hr not_active Application Discontinuation
-
2003
- 2003-09-09 HK HK03106404.4A patent/HK1054227A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
SK1182002A3 (en) | 2002-11-06 |
ATE423113T1 (de) | 2009-03-15 |
JP2003508353A (ja) | 2003-03-04 |
IL147495A0 (en) | 2002-08-14 |
RU2002105011A (ru) | 2004-01-20 |
NO20020214D0 (no) | 2002-01-15 |
MXPA02000888A (es) | 2002-07-30 |
PL354998A1 (en) | 2004-03-22 |
ZA200200543B (en) | 2003-08-27 |
CR6563A (es) | 2008-11-25 |
DE60041584D1 (de) | 2009-04-02 |
WO2001007436A2 (en) | 2001-02-01 |
IL147495A (en) | 2007-07-24 |
TR200200225T2 (tr) | 2002-06-21 |
NO20020214L (no) | 2002-04-02 |
CN1420882A (zh) | 2003-05-28 |
CA2382755A1 (en) | 2001-02-01 |
HK1054227A1 (zh) | 2003-11-21 |
HUP0203375A3 (en) | 2005-03-29 |
EP1208097B1 (en) | 2009-02-18 |
KR20020087041A (ko) | 2002-11-21 |
HRP20020076A2 (en) | 2003-12-31 |
WO2001007436A3 (en) | 2001-08-23 |
AU6462800A (en) | 2001-02-13 |
AU773227B2 (en) | 2004-05-20 |
JP4829449B2 (ja) | 2011-12-07 |
EP1208097A2 (en) | 2002-05-29 |
BG106340A (en) | 2002-10-31 |
BR0013179A (pt) | 2002-04-02 |
CZ2002323A3 (cs) | 2002-05-15 |
EE200200045A (et) | 2003-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0203375A2 (hu) | Szubsztituált oxoazaheterociklusos vegyületek | |
HUP0101810A2 (hu) | Helyettesített oxoazaheterociklusos xa faktor inhibitorok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0002530A2 (hu) | Gyulladásgátló hatású trifenil-propánamid-származékok | |
DE69628368D1 (de) | Heterocyclische Verbindungen, ihre Herstellung und Verwendung | |
MY140012A (en) | Heterocylic substituted phenyl methanones | |
DE3578425D1 (de) | Herstellung von clindamycin und analoge. | |
ATE307122T1 (de) | Isoxazolderivate und ihre verwendung als herbizide | |
KR880011123A (ko) | N- 벤즈히드릴- 치환된 헤테로사이클 유도체, 그의 제조방법 | |
LV10456A (lv) | Triazolpiridazina atvasinajumi to iegusanas panemiens un pielietojums | |
RS51358B (en) | N- (HETEROARYL) -1H-INDOL-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS A VANYLOID TRPV1 RECEPTOR LIGAND | |
Boyce et al. | Total synthesis of thiangazole, a novel naturally occurring HIV-1 inhibitor from Polyangium sp | |
DE69123315T2 (de) | 6,7-Dihydro-3-Phenyl-1,2-benzisoxazol-4(5H)-one und -ole, ein Verfahren für ihre Herstellung und ihre Verwendung als Arzneimittel | |
ATE81857T1 (de) | Hetaryl-oxy-beta-carbolinderivate, ihre herstellung und verwendung als arzneimittel. | |
ES2153424T3 (es) | Heterociclocromenos fotocromicos. | |
ES453690A1 (es) | Procedimiento para la preparacion de compuestos heterocicli-cos. | |
PT74199A (de) | Neue trisubstituierte pyrimido<5,4-d>pyrimidine ihre herstel- lung und ihre verwendung als arzneimittel | |
Grison et al. | Enantioselective synthesis of α, β-unsaturated γ-and δ-lactams | |
ATE77625T1 (de) | Kondensierte heterocyclische tetrahydroaminochinolinole und verwandte verbindungen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel. | |
DK1021404T3 (da) | Azetidinonderivater til behandling af HCMV-infektioner | |
IE781382L (en) | Indole derivatives | |
Tokumitsu | Reaction of. BETA.-nitro enamines with isocyanates, isothiocyanates and dimethyl acetylenedicarboxylate. | |
ES471403A1 (es) | Un procedimiento de preparacion de derivados de la tienopi- ridina | |
ES2168189A1 (es) | Derivados de piperazinona | |
ATE83232T1 (de) | Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel. | |
Reddy et al. | A NOVEL SYNTHESIS OF 4-CYANO-2-(2-HYDROXYBENZOYL) PYRIDO [1, 2-α]-BENZIMIDAZOLES FROM 3-FORMYLCHROMONE |